NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

Study Summary

This is a single arm, open-label, multi-center, Phase 1 study to determine the safety and tolerability of an experimental therapy called NKX019 (allogeneic CAR NK cells targeting CD19) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) or B cell acute lymphoblastic leukemia (B-ALL)

Conditions

Lymphoma, Non-Hodgkin B-cell Acute Lymphoblastic Leukemia Large B-cell Lymphoma Mantle Cell Lymphoma Indolent Lymphoma Waldenstrom Macroglobulinemia Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Aggressive Lymphoma Large-cell Lymphoma

Interventions / Drugs

NKX019

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment150 participants

Primary Completion—

Lead SponsorNkarta, Inc.

Data Retrieved2026-04-11 04:22:44.430452+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.